Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability up to 6 Years of Intravenous (i.v.) Secukinumab in Pediatric Participants With Juvenile Psoriatic Arthritis (JPsA). (NCT06751238)
An Open-label, Multicenter Study to Evaluate Pharmacokinetics, Safety and Tolerability up to 6 Years of Intravenous Secukinumab Infusions in Pediatric Participants With Juvenile Psoriatic Arthritis
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to determine the PK, safety and tolerability of multiple doses of intravenous (i.v.) secukinumab in pediatric participants with JPsA
Who can join: Review the eligibility criteria below.
Location: Loma Linda University Health — Loma Linda, California
Age range: 2 Years to 17 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (11 Sites)
- Loma Linda University Health — Loma Linda, California
- University of Florida — Gainesville, Florida
- Ann and Robert H Lurie Childs Hosp — Chicago, Illinois
- Col Uni Med Center New York Presby — New York, New York
- Levine Childrens Hospital — Charlotte, North Carolina
- Cincinnati Childrens Hospital — Cincinnati, Ohio
- Univ Hosp Cleveland Medical Center — Cleveland, Ohio
- Legacy Emanuel Research Hosp Portland — Portland, Oregon
- Childrens Hosp Pittsburgh UPMC — Pittsburgh, Pennsylvania
- Texas Arthritis Center — El Paso, Texas
- University of Utah — Salt Lake City, Utah
📞 Contact the Study Coordinator
Phone: (888) 669-6682
Email: novartis.email@novartis.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Juvenile Psoriatic Arthritis
- A Study of Ixekizumab (LY2439821) in Children With Juvenile Idiopathic Arthritis Categories of Enthesitis-related Arthritis (Including Juvenile Onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis — Rosario, Santa Fe Province
- A Study to Evaluate the Drug Levels, Efficacy, and Safety of Deucravacitinib (BMS-986165) in Pediatric Participants With Juvenile Psoriatic Arthritis — Lancaster, California
- A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab — Little Rock, Arkansas
Explore by condition: All Juvenile Psoriatic Arthritis clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.